Latest News and Press Releases

BOSTON and LOUISVILLE, Ky., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...

BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...

BOSTON and LOUISVILLE, Ky., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...

BOSTON and LOUISVILLE, Ky., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company, today presented a new analysis of HLA...

BOSTON and LOUISVILLE, Ky., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...

Provided initial clinical update from its Phase 3 (FREEDOM-1) clinical trial evaluating FCR001 in living donor kidney transplant patients Initiated Phase 2 (FREEDOM-2) clinical trial for FCR001 in...

BOSTON and LOUISVILLE, Ky., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...

First two Phase 3 patients treated with FCR001 more than 12 months prior to the data cutoff date both successfully weaned off all chronic immunosuppression (IS) without evidence of rejection and with...

BOSTON, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of...

Company will share first clinical update on Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipientsPoster with additional data from Phase 2 study follow-up to be presented at...